Company · Private
Tornado Therapeutics
Developing selective TORC1 inhibitors intended to improve immune function in older adults.
EvidenceEarlyHistory of endpoint misses
Listing
Private
Ticker
—
Headquarters
Boston, US
Founded
2020
Technology
mTOR inhibition / immune aging
Category
Market cap
Private
Longevity thesis
Selective mTOR inhibition can capture rapamycin's benefits without broad immunosuppression.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| TOR-114 | Phase 2 | Respiratory infection in older adults |
Recent developments
- 25 Jul 2026Started a Phase 2 in adults over 65.
Scientific evidence
EvidenceEarly
Previous efforts in this mechanism failed a pivotal endpoint; selectivity is the open question.
LONGEFI analysis
Historically the most disappointing longevity mechanism in the clinic. LONGEFI applies an elevated evidence bar here.
Analysis is research commentary. It is not investment advice or a recommendation.